Results 221 to 230 of about 10,543,759 (362)

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

Chemical classification program synthesis using generative artificial intelligence. [PDF]

open access: yesJ Cheminform
Mungall CJ   +5 more
europepmc   +1 more source

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

open access: yesMolecular Oncology, EarlyView.
RAS‐targeted therapies have become a clinical reality. Although promising results in patients have been achieved, there are still challenges ahead such as coping with drug resistance. Here we summarize selected RAS inhibitors targeting either individual KRAS mutant isoforms (KRASG12C, KRASG12D, KRASG12V) or exhibiting a wider inhibitory spectrum ...
Matthias Drosten, Mariano Barbacid
wiley   +1 more source

Meta-analysis of the impact of 9 medication classes on falls in elderly persons.

open access: yesArchives of Internal Medicine, 2009
J. Woolcott   +6 more
semanticscholar   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

open access: yesMolecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy